Efficacy and safety of oral melatonin in patients with severe COVID-19: a randomized controlled trial

Abstract Patients with COVID-19 have shown melatonin deficiency. We evaluated the efficacy and safety of administration oral melatonin in patients with COVID-19-induced pneumonia. Patients were randomly assigned in a 1:1 ratio to receive melatonin plus standard treatment or standard treatment alone. The primary outcomes were mortality rate and requirement of IMV. The clinical status of patients was recorded at baseline and every day over hospitalization based on seven-category ordinal scale from 1 (discharged) to 7 (death). A total of 226 patients (109 in the melatonin group and 117 in the control group) were enrolled (median age; in melatonin group: 54.60 ± 11.51, in control group: 54.69 ± 13.40). The mortality rate was 67% in the melatonin group and 94% in the control group (OR; 7.75, 95% CI, 3.27–18.35, P < 0.001). The rate of IMV requirement was 51.4% in the melatonin group and 70.9% in the control group, for an OR of 2.31 (95% CI, 1.34–4.00, P < 0.001). The median number of days to hospital discharge was 15 days (13–17) in the melatonin group and 21 days (14–24) in the control group (OR; 5.00, 95% CI, 0.15–9.84, P = 0.026). Time to clinical status improvement by ≥ 2 on the ordinal scale in was 12 days (9–13) in the melatonin group and 16 days (10–19) in the control group (OR; 3.92, 95% CI, 1.69–6.14, P = 0.038). Melatonin significantly improved clinical status with a safe profile in patients with severe COVID-19 pneumonia..

Medienart:

E-Artikel

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Zur Gesamtaufnahme - volume:31

Enthalten in:

Inflammopharmacology - 31(2022), 1 vom: 19. Nov., Seite 265-274

Sprache:

Englisch

Beteiligte Personen:

Ameri, Ali [VerfasserIn]
Frouz Asadi, Masoomeh [VerfasserIn]
Ziaei, Ava [VerfasserIn]
Vatankhah, Majid [VerfasserIn]
Safa, Omid [VerfasserIn]
Kamali, Manoochehr [VerfasserIn]
Fathalipour, Mohammad [VerfasserIn]
Mahmoodi, Masoumeh [VerfasserIn]
Hassanipour, Soheil [VerfasserIn]

Links:

Volltext [lizenzpflichtig]

Themen:

Antioxidant
COVID-19
Cytokine storm
Inflammation
Melatonin

Anmerkungen:

© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

doi:

10.1007/s10787-022-01096-7

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

OLC2134144106

Zugang & Verfügbarkeit




Zugehörige Publikationen/Bände

    Haven't found what you're looking for?